2023年4月10日,

KinoPharma,易威奇制药开始第二阶段的研究皮肤疣药物试验将证实药物的疗效治疗皮肤疣的候选人。显微照片的常见的疣。信贷:肾元/ commons.wikimedia.org。KinoPharma与磐制药合作已经开始一个候选药物的二期临床试验治疗皮肤疣,人类乳头状瘤病毒(HPV)感染。临床试验旨在评估药物的疗效。决定开始后的二期临床试验是确定药物在人类和动物的安全。公司也提交了一份通知药品和医疗器械的临床试验机构(PMDA),日本监管机构。2021年1月以来,两家公司一直致力于开发基于KinoPharma药膏的新概念的人乳头状瘤病毒的抗病毒药物针对人类宿主因素。新的药膏提出制定一个最佳的交付方法治疗HPV感染的皮肤和粘膜。去年8月,扩大合作与共同发展和商业化协议的签署促进治疗皮肤疣的临床开发。 Cutaneous warts are small proliferative non-cancerous lesions (benign tumours) of the skin. They are a type of infection caused by the HPV. Generally, the treatment includes cryotherapy using liquid nitrogen. It requires repeated procedures and usually causes pain. HPV infection is known to cause several diseases such as reproductive organ (cervical cancer), anogenital (condyloma acuminatum, anal cancer), and upper aerodigestive tract (oropharyngeal cancer), and skin (cutaneous warts) diseases. More than 100 different types of HPV have been identified, some of which may cause, while others may cause benign neoplasms. Share this article